辉瑞中国研发中心(CRDC)于2005年10月31日成立于上海,是世界一流的研发基地,主要为全球辉瑞药物研发提供支持工作,包括第I期到第IV期的临床试验的支持工作,并为辉瑞在中国和亚洲地区提供研究协作和战略合作的机会。
        2010年10月辉瑞中国研发中心在武汉光谷生物产业中心成立分部。同年,辉瑞中国研发中心还成立了一个世界性的负责全球药物注册准备的监管团队以及一支负责辉瑞亚太地区临床试验质量保障审查工作的团队。
        自成立以来,辉瑞中国研发中心积极与中国的合作伙伴开展生命科学领域的人才培养和发展,包括本地成长的科研工作者、生物统计师、医学专业人员、药学和其他生命科学领域的专业人员。另外,中心还与中国一流的科研人员和顶尖的研究机构进行合作,包括北京大学、清华大学、复旦大学、中科院生物物理研究所以及中科院上海生物化学和细胞生物学研究所等。通过这些合作,我们希望能为中国创新药物的研究创造良好的条件

        Established on October 31, 2005, Pfizer China Research and Development Center (CRDC) is a state-of-the-art facility in Shanghai, providing global drug development support capabilities, including support for Phase I-IV clinical trials, and research collaborations and strategic alliance opportunities to China and the Asia region.
        In October 2010, a significant R&D presence was opened in Wuhan Biolake. That same year, CRDC also established a worldwide regulatory operations team for global submission preparation and a quality assurance team for Pfizer’s clinical trials in the Asia-Pacific region.
        Since its establishment, CRDC works alongside Chinese partners to develop the skills and talents of local scientists, biostatisticians, medical professionals, pharmacists, and others with expertise in life sciences. CRDC collaborates with leading academic researchers and top institutions in China, including: Peking University, Tsinghua University, Fudan University, the Chinese Academy of Science Institute of Biophysics, and the Chinese Academy of Sciences Shanghai Institute of Biochemistry and Cell Biology, among others. Through working with these partners, Pfizer strives to create an environment that will nurture research and innovative drug development in China.

未经51job.com同意,不得转载本网站之所有招聘信息及作品;无忧工作网版权所有©1999-2019